Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to track Septerna’s latest clinical milestones but buried in 200-page disclosures? Early-stage biotech filings can overwhelm even seasoned analysts—especially when every 8-K update or Form S-3 shelf registration may alter dilution risk. Septerna’s Native Complex Platform science adds another layer of GPCR jargon that’s tough to decode.
Stock Titan solves this problem by pairing every real-time SEC upload with AI-powered summaries that explain each section in plain English. Whether you need the Septerna quarterly earnings report 10-Q filing to see R&D burn, or want “Septerna insider trading Form 4 transactions” before the market reacts, our engine highlights the numbers—and the context—instantly.
Explore a complete set of documents:
- 10-K annual report—find pipeline progress, risk factors, and “Septerna annual report 10-K simplified”
- 10-Q quarterly statements—monitor cash runway and trial spend with “Septerna earnings report filing analysis”
- 8-K material events—get “Septerna 8-K material events explained” for partnership announcements
- DEF 14A proxy—review “Septerna proxy statement executive compensation”
- Form 4—track “Septerna executive stock transactions Form 4” in real time
Our platform doesn’t stop at raw data. AI comparisons spotlight quarter-over-quarter shifts, and expert annotations flag clinical trial milestones hidden deep in footnotes—so you can act before headlines break. From “understanding Septerna SEC documents with AI” to setting custom alerts for “Septerna Form 4 insider transactions real-time”, everything is one click away. Save hours, stay informed, and make decisions with confidence.
Septerna, Inc. announced that it released its financial results and business highlights for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to this Current Report. The filing states the press release is being furnished (and not "filed") for purposes of the Exchange Act, and the 8-K itself does not include detailed financial statements or metrics. Readers should consult Exhibit 99.1 for the substantive results and disclosures.
Insider Trading Alert: Shalini Sharp, Director at Septerna, was granted 16,623 stock options on June 17, 2025. The options have an exercise price of $10.24 per share and will expire on June 16, 2035.
Key details of the stock option grant:
- Vesting occurs in full upon the earlier of June 17, 2026, or the next annual stockholder meeting
- Vesting is contingent on continued service with the company
- The options represent the right to purchase 16,623 shares of common stock
- Transaction was filed under Form 4 as required by Section 16(a) of the Securities Exchange Act
This grant appears to be part of the company's director compensation program. The filing was completed through an attorney-in-fact, Jeffrey Finer, on June 20, 2025.
Director Jeffrey K. Tong of Septerna received a stock option grant on June 17, 2025, representing a significant insider transaction. The details include:
- Granted 16,623 stock options to purchase common stock
- Exercise price set at $10.24 per share
- Options expire on June 16, 2035
- Vesting schedule: 100% vests upon earlier of June 17, 2026 or next annual stockholder meeting
- Vesting conditional on continued service with company
This Form 4 filing represents a standard director compensation arrangement through equity incentives, aligning the director's interests with shareholders. The one-year cliff vesting structure suggests a retention mechanism while promoting long-term value creation.
Director Bernard Coulie of Septerna received a stock option grant on June 17, 2025, according to a Form 4 filing. The grant consists of 16,623 stock options with an exercise price of $10.24 per share.
Key details of the option grant:
- Exercise Price: $10.24 per share
- Expiration Date: June 16, 2035
- Vesting Schedule: Full vesting upon the earlier of (i) June 17, 2026 or (ii) the next annual stockholders meeting
- Vesting Condition: Subject to continued service with the company
This appears to be a standard director compensation grant. The filing was signed by Jeffrey Finer as attorney-in-fact on June 20, 2025. The transaction represents direct ownership of the derivative securities.
Director Abraham Bassan of Septerna received a stock option grant for 16,623 shares of common stock on June 17, 2025. The options were granted with an exercise price of $10.24 per share and will expire on June 16, 2035.
Key terms of the option grant:
- Full vesting occurs at the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on continued service with the company
- The options represent a new derivative security position, with direct ownership
This Form 4 filing, signed by Jeffrey Finer as attorney-in-fact on June 20, 2025, reports the transaction under Section 16(a) of the Securities Exchange Act of 1934. The grant appears to be part of the company's director compensation program.
Director Alan Ezekowitz of Septerna received a stock option grant on June 17, 2025, representing a significant insider transaction. Key details include:
- Granted 16,623 stock options to purchase common stock at an exercise price of $10.24 per share
- Options will vest in full upon the earlier of:
- June 17, 2026
- The company's next annual stockholders meeting
- Options expire on June 16, 2035
- Vesting is contingent on continued service with the company
This equity compensation grant aligns with standard director compensation practices and serves to align the director's interests with those of shareholders. The filing was executed by Jeffrey Finer as attorney-in-fact on June 20, 2025.
FAQ
What is the current stock price of Septerna (SEPN)?
What is the market cap of Septerna (SEPN)?
